title: Differential Mobility Spectrometry Coupled with Multiple Ion Monitoring in Regulated LC-MS/MS Bioanalysis of a Therapeutic Cyclic Peptide in Human Plasma.
abstract: A differential mobility spectrometry (DMS) in combination with a multiple ion monitoring (MIM) method was developed and validated for quantitative LC-MS/MS bioanalysis of pasireotide (SOM230) in human plasma. Pasireotide, a therapeutic cyclic peptide, exhibits poor collision-induced dissociation (CID) efficiency for multiple reaction monitoring (MRM) detection. Therefore, in an effort to increase the overall sensitivity of the assay, a DMS-MIM approach was explored. By selecting the most abundant doubly charged precursor ion in both the Q1 and Q3 of the mass analyzer in MIM and combining the DMS capability to significantly reduce the high matrix/chemical background noise, this new LC-DMS-MIM method overcomes the sensitivity challenge in the typical MRM method due to poor CID fragmentation of the analyte. Human plasma was spiked with pasireotide with concentrations in the range 0.01-50 ng/mL. Weak cation-exchange solid-phase extraction was employed for sample preparation. The sample extracts were analyzed with a SCIEX QTRAP 6500 system equipped with an ESI source and DMS device. The separation voltage and compensation voltage of the DMS and other parameters of the MS system were optimized to maximize signal responses. The performance of the LC-DMS-MIM assay for quantitative analysis of pasireotide in human plasma was evaluated and compared to those obtained via LC-MRM and LC-MIM without DMS. Overall, the assay sensitivity with DMS-MIM was approximately 5-fold better than that observed in MRM or MIM without DMS. The assay was validated with accuracy (% bias) and precision (% CV) of the QC results at eight concentration levels (0.01, 0.02, 0.05, 0.15, 0.3, 1.5, 15, and 37.5 ng/mL) evaluated ranging from -4.8 to 5.0% bias and 0.7 to 8.6% CV for the intraday and interday runs. The current LC-DMS-MIM workflow can be expanded to quantitative analysis of other molecules that have poor fragmentation efficiency in CID.
authors.affiliation: Early Bioanalytics and Technology, Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research , One Health Plaza, East Hanover, New Jersey 07936, United States.
authors.forename: Yunlin
authors.initials: Y
authors.lastname: Fu
authors.affiliation: Sciex , 500 Old Connecticut Path, Framingham, Massachusetts 01701, United States.
authors.forename: Yuan-Qing
authors.initials: YQ
authors.lastname: Xia
authors.affiliation: Early Bioanalytics and Technology, Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research , One Health Plaza, East Hanover, New Jersey 07936, United States.
authors.forename: Jimmy
authors.initials: J
authors.lastname: Flarakos
authors.affiliation: Early Bioanalytics and Technology, Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research , One Health Plaza, East Hanover, New Jersey 07936, United States.
authors.forename: Francis L S
authors.initials: FL
authors.lastname: Tse
authors.affiliation: Sciex , 500 Old Connecticut Path, Framingham, Massachusetts 01701, United States.
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Miller
authors.affiliation: Sciex , 500 Old Connecticut Path, Framingham, Massachusetts 01701, United States.
authors.forename: Elliott B
authors.initials: EB
authors.lastname: Jones
authors.affiliation: Early Bioanalytics and Technology, Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research , One Health Plaza, East Hanover, New Jersey 07936, United States.
authors.forename: Wenkui
authors.initials: W
authors.lastname: Li
mesh_terms: D006801:Humans; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000097:blood; D053719:Tandem Mass Spectrometry / Q000295:instrumentation / Q000379:methods
chemical_list: D013004:Somatostatin; C517782:pasireotide